{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-023415","form_type":"8-K","ticker":"CLNN","cik":"0001822791","company_name":"Clene Inc.","filed_at":"2023-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.458634+00:00","generated_at":"2026-06-11T12:26:27.241813+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Clene reports Q2 net loss of $25.1M; ALS NfL biomarker positive; cash $49.2M","bullets":["Net loss of $25.1M ($0.29 per share) versus $4.5M loss in Q2 2022; R&D down to $6.6M.","Cash, equivalents and marketable securities $49.2M after $40M June public offering; potential $130M more from warrants.","CNM-Au8 reduced plasma neurofilament light chain (NfL) vs placebo (p=0.04) in HEALEY ALS trial at 24 weeks.","Phase 2 RESCUE ALS results published in Lancet eClinicalMedicine; preparing for FDA ALS regulatory meetings.","NMSS grant funds Cohort 2 of REPAIR-MS for progressive MS; multiple near-term data announcements expected."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-023415","json":"https://secwatch.observer/filing/0001437749-23-023415.json","markdown":"https://secwatch.observer/filing/0001437749-23-023415.md","text":"https://secwatch.observer/filing/0001437749-23-023415.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1822791/000143774923023415/0001437749-23-023415-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1822791/000143774923023415/clnn20230602_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T12:26:27.241813+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fdf4b6bcfa6400189961659f5c76ac3e7a54e0d5","claim":"Clene Inc. reported second quarter 2023 results: net income $25.1 million, EPS $0.29 per share.","evidence_excerpt":"Clene reported a net loss of $25.1 million , or $0.29 per share, for the quarter ended June 30, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1822791/000143774923023415/0001437749-23-023415-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter 2023"},{"label":"Net income","value":"$25.1 million"},{"label":"EPS","value":"$0.29 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}